MIRA Pharmaceuticals Reports Positive Preclinical Data for Optimized Oral SKNY-1 Formulation
MIRA is trading near its 52-week low of $0.9 (5.0% above the low) on light trading volume (0.4× avg).
Summary
MIRA Pharmaceuticals announced positive preclinical results for the optimized oral formulation of SKNY-1, its drug candidate for obesity and addiction, demonstrating favorable pharmacokinetics and a differentiated safety profile.
Key Events · Product Development and Regulatory · MIRA
-
Positive SKNY-1 Formulation Data
Preclinical studies showed favorable oral bioavailability, reproducible systemic exposure, robust brain penetration, and substantial liver exposure for the optimized oral formulation of SKNY-1.
-
Once-Daily Dosing Potential
Peak plasma concentrations support the potential for convenient once-daily oral dosing, observed approximately six to twelve hours after administration.
-
Differentiated Safety Profile
SKNY-1 did not produce anxiety-related behavioral effects in a validated preclinical model, distinguishing it from earlier CB1-targeting therapies associated with neuropsychiatric adverse effects.
-
Strengthens Development Profile
These pharmacokinetic findings complement previously reported efficacy and behavioral studies, reinforcing SKNY-1's potential as a differentiated oral therapeutic for obesity and addiction.
Analysis · MIRA · Life Sciences
This filing provides crucial new preclinical data for SKNY-1, a key drug candidate for obesity and addiction. The demonstrated favorable oral bioavailability, robust brain and liver penetration, and potential for once-daily dosing significantly strengthen its development profile. Importantly, the data also highlights a differentiated safety profile, avoiding the neuropsychiatric side effects seen with earlier CB1-targeting therapies, which is a major de-risking factor for the program. This progress is vital for a clinical-stage micro-cap company, especially given its previous "going concern" status, as it validates the potential of its pipeline.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MIRA was trading at $0.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.7M. The 52-week trading range was $0.90 to $2.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.